Brain-Computer Interfaces Are Red Hot.
But How Close Are We Really?

Opening the Floodgates

In January 2026, Neuralink announced that its PRIME Study had enrolled 21 participants across four countries — the United States, Canada, the United Kingdom, and the United Arab Emirates. The company performed 17 implant procedures in 2025 alone. By July 2026, Neuralink had successfully completed its 20th human implantation. The field is moving faster than even its most optimistic observers had predicted.

The field is undeniably hot. But the gap between medical-grade BCI and consumer-grade BCI remains vast. Here’s where the technology actually stands — and what it will take to cross the chasm.

What Neuralink Has Actually Achieved

The PRIME Study (Precise Robotically Implanted Brain-Computer Interface) is evaluating the N1 Implant, a fully implantable, intracortical BCI designed for individuals with severe neurological conditions such as spinal cord injury and motor neurone disease. The device enables users to control computer cursors and other digital devices using only their thoughts. It consists of a biocompatible enclosure implanted in the skull, with 1,024 electrodes distributed across 64 threads, each thinner than a human hair.

The results have been remarkable for the participants involved. One UK trial participant, Sebastian Gomez — a medical student who lost the use of his limbs after a diving accident — described the experience as a “massive change” and “a new piece of hope.” The lead neurosurgeon called the level of control “remarkable for this stage of development.”

Multiple Neuralink participants have achieved information transfer rates exceeding 10 bits per second — matching or exceeding the 8–10 BPS average of able-bodied people using a computer mouse. One participant, Nick, reached over 10 BPS within his first week of using the BCI. He was able to feed himself, play video games, and navigate a digital environment using only his thoughts.

Neuralink’s Blindsight implant, aimed at restoring vision for completely blind individuals, is scheduled for its first patient trial in 2026. The company has also received official approvals for human clinical trials in the U.S.

The Chinese Counterpart: A Different Path

While Neuralink dominates Western headlines, Chinese BCI players are advancing rapidly — but with a fundamentally different approach.

NeuroXess (脑虎科技), based in Shanghai, has completed more than 50 clinical trials and is developing what it calls a “fully implanted, fully wireless, fully functional” BCI system. The company’s first patient, implanted in late 2025, achieved a brain control speed of 5.2 bits per second after 17 days of training — roughly half of Neuralink’s peak, but achieved with a less invasive approach.

In April 2026, NeuroXess announced its second clinical breakthrough: a 29-year-old quadriplegic art teacher regained the ability to eat independently and paint using a BCI-driven functional electrical stimulation system. The system achieved a full-link latency of under 50 milliseconds — considered world-class for a minimally invasive system.

The technical differences are significant. NeuroXess uses flexible cortical electrodes placed on the brain’s surface (under the dura but not penetrating brain tissue), avoiding deep brain damage. The battery and processor are implanted under the chest skin, keeping heat sources away from the brain. This trade-off — lower signal resolution in exchange for reduced surgical risk — defines the Chinese approach.

NeuroXess is also moving toward mass production. The company plans to begin operating a 14,300-square-meter manufacturing facility in Jiangxi province in the second half of 2026, with eventual annual production capacity at the scale of tens of thousands of units.

The Two Paths: Implantable vs. Wearable

The U.S. and China are pursuing fundamentally different BCI strategies.

The U.S. approach — led by Neuralink — focuses on invasive implants. These offer higher signal quality and performance but require brain surgery and carry significant medical risk.

The Chinese approach has been more diversified. While NeuroXess pursues minimally invasive implants, other Chinese companies are focusing on non-invasive wearables. BrainCo, based in Hangzhou and founded at Harvard’s Innovation Lab, produces prosthetic limbs and wearable BCI devices that don’t require surgery. These devices are already commercially available and are being used in education, rehabilitation, and consumer applications.

The divergence reflects different priorities. Jefferies, in a July 2026 report, identified implantable and ultrasound-based BCI as the most promising directions. But China has officially incorporated BCI into its five-year plan and appears to be prioritizing commercialization and accessibility over peak performance. The result is a two-track race: one track for medical breakthroughs, another for market penetration.

The Consumer-Grade Gap

Here’s where the “hot” narrative meets reality.

At the 2026 China International Import Expo, consumer-grade BCI products were a major attraction. Visitors could use brainwaves to order coffee, control devices through concentration, or match music to their mood. One booth featured a popcorn machine operated entirely by thought. These devices are non-invasive, safe, and commercially available today.

But the gap between these “fun” consumer applications and Neuralink-style medical implants is enormous. Non-invasive devices have limited signal resolution. They can detect broad states — relaxed, focused, stressed — but cannot enable precise control of a cursor or robotic arm.

BCI is not one technology. It’s a spectrum.

At one end: non-invasive wearables — safe, cheap, limited. At the other end: invasive implants — powerful, risky, expensive. In between: minimally invasive approaches like NeuroXess’s surface electrodes or intravascular electrodes being explored by some companies.

Each has its own timeline. Consumer wearables are already here. Medical implants are in clinical trials. Consumer-grade implants — the kind that would let you control your phone with your thoughts without a medical condition — are not here yet, and they are not coming next year.

The Real Story

The BCI field is hot because the science is advancing — not because the products are ready.

Neuralink has proven that invasive BCI can work in humans. NeuroXess has proven that minimally invasive BCI can be replicated and scaled. Consumer wearables have proven that there’s a market for “light” BCI applications.

But the gap between “works in a clinical trial” and “works in your living room” is measured in years, not months. Regulatory pathways are long. Safety requirements are stringent. Manufacturing at scale is hard. And the fundamental challenge — decoding neural signals reliably enough for everyday use — is still being solved.

The field is hot. The progress is real. But the consumer-grade BCI future is still ahead of us — and it will arrive piece by piece, not all at once.